 | |
| Clinical data | |
|---|---|
| Trade names | Vonjo |
| Other names | SB1518 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C28H32N4O3 |
| Molar mass | 472.589 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pacritinib, sold under the brand nameVonjo, is ananti-cancer medication used to treatmyelofibrosis.[1][2][3][4]
It is amacrocyclicprotein kinase inhibitor. It mainly inhibitsJanus kinase 2 (JAK2) andFms-like tyrosine kinase 3\CD135 (FLT3).
Common side effects include diarrhea, low platelet counts, nausea, anemia, and swelling in legs.[2]
Pacritinib inindicated to treat adults who have a rare form of a bone marrow disorder known as intermediate or high-risk primary or secondary myelofibrosis and who have platelet (blood clotting cells) levels below 50,000/μL.[1][2]
The effectiveness and safety of pacritinib were demonstrated in a study that included 63 participants with intermediate or high-risk primary or secondary myelofibrosis and low platelets who received pacritinib 200 mg twice daily or standard treatment.[2] Effectiveness was determined based upon the proportion of participants who had a 35% or greater spleen volume reduction from baseline to week 24.[2] Nine participants (29%) in the pacritinib treatment group had a 35% or greater spleen volume reduction, compared to one participant (3%) in the standard treatment group.[2]
The U.S.Food and Drug Administration (FDA) granted the application for pacritinibpriority review,fast track, andorphan drug designations.[2][5]
Pacritinib is theInternational nonproprietary name (INN).[6][7]
This article incorporates text from this source, which is in thepublic domain. | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byadding missing information. |
